Carvacrol Alleviates Prostate Cancer Cell Proliferation, Migration, and Invasion through Regulation of PI3K/Akt and MAPK Signaling Pathways.
TRPM7 is a potential therapeutic target for treatment of prostate cancer. In this study, we investigated the effects of nonselective TRPM7 inhibitor carvacrol on cell proliferation, migration, and invasion of prostate cancer PC-3 and DU145 cells. Our results showed that carvacrol blocked TRPM7-like currents in PC-3 and DU145 cells and reduced their proliferation, migration, and invasion. Moreover, carvacrol treatment significantly decreased MMP-2, p-Akt, and p-ERK1/2 protein expression and inhibited F-actin reorganization. Furthermore, consistently, TRPM7 knockdown reduced prostate cancer cell proliferation, migration, and invasion as well. Our study suggests that carvacrol may have therapeutic potential for the treatment of prostate cancer through its inhibition of TRPM7 channels and suppression of PI3K/Akt and MAPK signaling pathways.
Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
Yun
Y
Luo
Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
Jie-Ying
JY
Wu
Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
Min-Hua
MH
Lu
Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China.
Zhi
Z
Shi
Department of Kidney Transplantation, The 3rd Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
Ning
0000-0002-8786-7445
N
Na
Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, China.
Jin-Ming
0000-0003-4420-3152
JM
Di
D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D000081007:Cymenes; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008856:Microscopy, Fluorescence; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D039821:Monoterpenes / Q000633:toxicity*; D018408:Patch-Clamp Techniques; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D050053:TRPM Cation Channels / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
D000081007:Cymenes; D020778:Matrix Metalloproteinase 2; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D039821:Monoterpenes; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D034741:RNA, Small Interfering; D050053:TRPM Cation Channels; C073316:carvacrol; C486584:Trpm7 protein, rat